NCT06291870 Predictors of Post-COVID-19 Clinical and Cognitive Consequences
| NCT ID | NCT06291870 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Post Acute Sequelae of SARS CoV 2 Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-01-19 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2023-01-19 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients. These sequelae may be present four or more weeks after SARS-COV-2 infection, including patients who had initial mild or asymptomatic acute infection. However, there is complete absence of data whether chronic sleep changes due to COVID-19 infection may influence these physical and mental health consequences. While fatigue is one of the common post-COVID conditions, there are no systematic examinations of sleep disturbances in COVID-19 survivors. This will be a pilot observational retrospective and prospective cohort study, to systematically assess if sleep disturbances and severity of sleep apnea comprise a modifiable facet of PASC as well as the short-term and longer-term effects of COVID-19 infection itself on sleep, cognitive function, exercise capacity and lung function.
Eligibility Criteria
Inclusion Criteria: * All individuals 18 years or older, with prior history of COVID-19 infection diagnosis * Both genders including all racial and ethnic groups * Patients with OSA (apnea hypopnea index of 5/hour on polysomnography) with history of COVID-19 infection will be eligible with prior history of COVID-19 infection and without COVID-19 for Aim 2 Exclusion Criteria: * Inability to give consent * Active suicidal symptoms * Children of all ages * Pregnant women
Contact & Investigator
Susmita Chowdhuri, MD MS
PRINCIPAL INVESTIGATOR
John D. Dingell VA Medical Center, Detroit, MI
Frequently Asked Questions
Who can join the NCT06291870 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Post Acute Sequelae of SARS CoV 2 Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06291870 currently recruiting?
Yes, NCT06291870 is actively recruiting participants. Contact the research team at ruchi.rastogi@va.gov for enrollment information.
Where is the NCT06291870 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT06291870 clinical trial?
NCT06291870 is sponsored by VA Office of Research and Development. The principal investigator is Susmita Chowdhuri, MD MS at John D. Dingell VA Medical Center, Detroit, MI. The trial plans to enroll 200 participants.